We rank companies based on fund manager, research analyst and news sentiment
BDRX

Biodexa Pharmaceuticals
BDRX

$0.77
2.39%
 

About: Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Employees: 26

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

187% more capital invested

Capital invested by funds: $58.9K [Q3] → $169K (+$110K) [Q4]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

40% more funds holding

Funds holding: 5 [Q3] → 7 (+2) [Q4]

0.05% more ownership

Funds ownership: 0.01% [Q3] → 0.07% (+0.05%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$8
946%
upside
Avg. target
$8
946%
upside
High target
$8
946%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Ladenburg Thalmann
Aydin Huseynov
946%upside
$8
Buy
Initiated
8 Feb 2024

Financial journalist opinion

Based on 3 articles about BDRX published over the past 30 days

Neutral
GlobeNewsWire
4 months ago
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of exclusive, worldwide license to Tolimidone, Phase II Ready Type I Diabetes clinical program CARDIFF, United Kingdom, Dec. 21, 2023 (GLOBE NEWSWIRE) - Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Biodexa. Biodexa also announced the closing under the assignment and exchange agreement (the “Assignment and Exchange Agreement”) with Adhera Therapeutics, Inc. (“Adhera”) and certain secured noteholders (the “Secured Noteholders”), pursuant to which Adhera assigned all of its rights to the compound Tolimidone to Biodexa, and the related license agreement (the “License Agreement”) with Melior Pharmaceuticals I, Inc. (“Melior”), pursuant to which Biodexa obtained an exclusive, worldwide, sublicensable right to develop, manufacture, commercialize, or otherwise exploit products containing Tolimidone for any field.
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option